arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Niagen Bioscience, Inc.

NAGE
$3.12 ▲ +0.08 (+2.80%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Niagen Bioscience, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $249.3M
Dividend Yield
Revenue Growth 3.3%
Op. Margin 5.0%
ROIC 1.8%
FCF / Share $-0.01
Trailing P/E 39.0x
Price / Book 3.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.47M
↑ +3.3%
Net Income Profit after all expenses
$6.32M
↑ +24.8%
Operating Margin Operating profit as % of sales
5.0%
↓ -58.5% 62th
FCF / Share Free cash flow per share
$-0.01
↓ -132.3%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
65
Returns
89
Financial Health
100
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters